Patents

All our compounds are protected by international patent.

The international PTC/EP2012/055570 patent request, has been approved as number WO2012130912.

Currently, the patent has been granted in the following countries:

• USA, US9440966 (B2) (pdf)
• Europe, EP2691394 (B1)
• Japan, JP6049216 (B2) (pdf)
• Canada, 2,831,716
• Australia, AU2012234230 (B2) (pdf)
• Russia, RU2615136 (C2) (pdf)
• Israel, IL228630 (pdf)
• South Korea, KR101784284 (B1) (pdf)
• Mexico, MX349254 (pdf)
• China, 201710886050.8 (pdf)

The use of all the compounds is protected for the treatment of the metabolic syndrome in general and for specific etiologies associated with the syndrome including NAFLD, NASH, obesity, hypertension, dyslipidemia and type 2 diabetes.

New International Patent PCT/EP2018/053990 of NAFLD and NASH granted in USA, US10857136 (B2) (pdf), Europe (EP3595660B1), Japan (JP7343902) and Canada (CA3053059).